Nova Eye Medical (EYE) Discussion, page-802

No problem, it seems to be very fast. The devices are disposable so no big initial cash outlay for doctors (recurring revenue for us though) and very easy to learn (from my understanding a surgeon can be trained within an hour to use the device). Surgeons don't ever use just one MIGS device either so they don't need to get rid of their iStents and OMNIs if they want to use iTrack Advance.

I honestly would not be surprised if we see sales far higher than that figure. It's very hard to tell so early on but I see no reason that they shouldn't at least double revenue in FY24 if they properly execute their sales strategy. Imo iTrack Advance is a far superior device to alternatives and doctors will rapidly make the shift to it. Canaloplasty itself is only like 1% of the total glaucoma treatment market at the moment so there is an enormous amount of room to grow here.